

SHINGLES CLINICAL TRIAL

(Varicella Zoster Virus)

A new clinical trial is available for patients diagnosed with shingles.

The clinical trial is a Phase IB, Double-Blind, Randomised, Placebo-Controlled study to evaluate the safety and tolerability of Solexan™ when administered topically to acute Varicella Zoster Virus (Shingles) lesions.

There will be 30 participants in total (20 active participants and 10 placebo participants).



KEY INCLUSION CRITERIA:

- Patients 18 years of age or older
- Patients diagnosed with shingles (Varicella Zoster Virus), with at least three distinct visible lesions on the torso, trunk, arms, or legs
- Patients' shingles symptoms (lesions/rash) must have appeared **within five days** of starting the study

KEY EXCLUSION CRITERIA:

- Patient is diagnosed with fibromyalgia
- Patient is taking, or planning to take, any medication or drugs that could impact how their body experiences pain such as opioid medication, TCAs, anticonvulsants, topical or oral steroidal anti-inflammatories, and lidocaine-containing dermal preparations (Famciclovir is accepted and NSAIDs/simple analgesics for shingles related pain)
- Patient demonstrates evidence of other clinically significant active infection(s)
- Patient has birthmarks, tattoos, wounds, or other skin blemishes or conditions at the planned treatment site
- Patient has a known cancer diagnosis and is currently receiving or has received anti-cancer therapy within 12 months of Screening
- Female patient who is pregnant or breast-feeding, or intends to become pregnant
- Patients who return a positive urine drug screen at pre-dose on Day 1 to recreational drugs (particularly cannabinoids or endocannabinoids)

PATIENT PARTICIPATION INVOLVES:

- A site screening visit (approx 2 hours)
- A randomisation and treatment period of 10 days, which includes:
 - Day 1 - Treatment of investigational product or placebo begins (patients have a 2:1 chance of receiving the investigational product)
 - Patients are required to apply the topical foam (investigational product or placebo) twice per day, with one application in the morning between 6am – 11am and another in the evening between 5pm – 10pm, for 10 consecutive days (at home or in the clinic)
 - Day 5 - Site visit
 - Day 11 - Site visit
- A follow-up site visit on Day 30
- Patients must maintain a study diary from Day 1 to Day 11, and then on Day 30

Referring your patients could potentially help advance medical breakthroughs for the treatment of shingles pain.

Find out more about this clinical trial at EVRIMA.COM/SHINGLES-STUDY

This trial has been approved by an independent ethics committee.



LEARN MORE

WNTR-VZV-001_Evrima Site Poster_V2.0_25MAR2024